Circuit Confirms

Federal Circuit Confirms Generic Drugmakers Can Deduct Hatch-Waxman Litigation Costs

In a landmark decision, the Federal Circuit has ruled that generic pharmaceutical companies may deduct legal expenses incurred in defending Hatch-Waxman patent litigation as ordinary and necessary business expenses. The ruling, which affirms a lower court's decision in favor of Actavis Laboratories FL, Inc., clarifies…